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SUMMARY
Long term oxygen therapy (LTOT) has been shown to prolong survival and to improve quality
oflife in patients with chronic obstructive pulmonary disease (COPD) andin respiratory failure.
InNorthernIrelandoxygenconcentratorshavebeenavailable onprescriptionsinceAugust1986,
initiallyonarestrictedbasisfromhospitalphysiciansonly.Thiswasfollowedbyopenprescribing
from April 1989, when concentrators could be prescribed by general practitioners. This study
examined prescribinghabitsofLTOT duringbothperiods, andpatientsurvival. Case notesofall
prescriptions of oxygen concentrators in Northern Ireland (to April 1991) were reviewed.
Prescription criteria and advice regarding usage during both periods were analysed. A
questionnairesurveyofsubjectsduringopenprescribingdocumented theadvicegivenatthetime
ofprescription and current usage. 164 charts of178 total installations were available for review.
During both periods many concentrators were installed without adherence to the prescribing
criteria at the time (75% restricted, 48% open). The majority of these were on the advice of a
consultant respiratory physician and only 14 were prescribed directly by GPs. 89 of91 subjects
receiving current LTOT during the study period completed questionnaires. Of the subjects
prescribed LTOT during the restricted period, 2 subjects are still alive (median survival 19 m,
range 0-104). From the open period, survival data was available on 107 of 129 subjects with 17
still alive (median survival 22 m, range 0-94). This study documents an inadequate rate of
prescribing and a lack ofconformity to guidelines in the provision ofLTOT in Northern Ireland.
We would suggest that familiarisation with the prescribing criteria, formal written advice at the
time of prescription, appropriate follow up to ensure adequate supplementation and regular
patient education on the use of LTOT would address these problems to a substantial degree.
INTRODUCTION
Long term oxygen therapy (LTOT) has been
shown toprolong survival andtoimprove quality
of life in patients with COPD and in respiratory
failure.",2 Following these studies, recom-
mendations for the prescription of oxygen
concentratorswerepublishedbyhealthauthorities
and scientific societies.3 Oxygen concentrators
became available on prescription in England and
Wales on 1st December 1985. Scotland and
Northern Ireland had separate arrangements. In
Northern Ireland, from August 1986 to April
1989, a period of "restricted" prescribing was
introduced during which the installation of an
oxygen concentrator could only be initiated by a
consultant physician. Following this, "open"
prescribing was introduced, during which GPs
could prescribe concentrators, with advice from
the Department ofHealth that the installation be
recommended by a consultant respiratory
physician. This study reports the prescribing
habits ofLTOTduring both these periods andthe
survival of subjects prescribed LTOT.
METHODS
All prescriptions of oxygen concentrators in
Northern Ireland are processed by the Central
Services Agency in Belfast, thus enabling the
identification of all recipients of LTOT. Case
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notes were obtained and reviewed where
available. Prescription criteria and advice
regarding usage during both the restricted and
open (to April 1991) periods were analysed.
Spirometric and blood gas data are the values
nearest in time to the prescription of LTOT. All
subjects receiving LTOT between August 1989
and April 1991 were sent a questionnaire
concerning the advice given at the time of
prescription and current usage. A failure to reply
prompted a second questionnaire, and if again
there was no reply, a home visit was made.
RESULTS
The criteria for prescription of LTOT by the
Ulster Thoracic Society (UTS) during the period
of restricted prescribing are given in Table I.
Subsequently, the guidelines were modified and
the absolute and relative indications for the
prescription ofLTOT during the open period are
also given in Table I. The total number of
installations duringthe studyperiodwas 178, and
of these 164 charts (44 [90%] restricted and 120
[93%] open) were available for review. The
diagnoses for the study subjects in both the
restricted and open periods are given in figure 1.
Mean spirometric and arterial blood gases for
both periods are given in Table II.
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Fig 1. Diagnosticgroupsforwhichoxygenconcentrators
were provided (open columns - restricted
prescribing, closed columns - open prescribing).
During the restricted period, 11 (25%) subjects
fulfilledtheUTS arterialbloodgas (ABG)criteria
at the time ofprescription and 25 (57%) did not.
Eight (18%) subjects had no record of ABG
analysis, thus by definition did not fulfil the
prescribing criteria. 19 (43%) subjects would
have fulfilled present ABG criteria. During the
restricted period, spirometric criteria were not
specifiedby the UTS. On review ofthe charts, 28
(64%) had spirometry measured and of these 22
(50%) fulfilled the current criteria.
TABLE I
Criteriaforprescription oflong term oxygen therapy during restrictedprescribing and open
prescribing (defined by the Medical Research Council study and Nocturnal Oxygen Therapy trial).
Restricted prescribing Usually COPD with or without right heart
failure, whose lifestyle or work is severely
limited
Baseline steady state PaO2 on room air < 6 kPa
No smoking
Open prescribing Absolute FEVI < 1.51 / FVC < 2.01
PaO2 < 7.3 kPa
PaCO2 > 6.0 kPa
Oedema
Clinically stable
Repeated measurements
Optimal therapy
No smoking
Relative As above without hypercapnia or oedema
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TABLE II
Mean spirometric and arterial blood gases (± standard deviation (SD))for subjects during the
periods ofrestricted and open prescribing.
Restricted (SD) Open (SD)
Installations 49 129
Female 19 49
Age (y) at prescription 60 (12) 65 (12)
FEV, (1) 0.92 (0.7) 0.94 (0.66)
PaO2(kPa) 6.45 (1.03) 6.56 (1.76)
PaCO2 (kPa) 6.33 (1.56) 6.6 (1.68)
Intheopenperiod, 62 (52%) subjects fulfilledthe
ABG criteria and 24 (20%) did not meet the
criteria. A further 34 (28%), had no record of
ABG analysis, thusby definitiondidnotfulfil the
prescribingcriteria. Spirometric criteriaweremet
by 55 (46%) subjects but not by nine (7%, 5 with
pulmonary fibrosis) whilst a further 56 (47%),
had no record of spirometry and hence did not
fulfil the prescribing criteria. 38 (32%) subjects
fulfilled all prescribing criteria.
Of the 115 prescriptions issued on the advice of
hospital physicians, only eight were prescribed
by a non-respiratory consultant. Ofthese, all had
ABG, and three did not fulfil the criteria. Four
had spirometry with one subject fulfilling all
criteria.
Of the 14 general practitioner requests, seven
medical charts were available for review. Two
subjectshadABGmeasurements andonefulfilled
thecriteria. Twohad spirometry andone fulfilled
the criteria.
91 subjects currently receiving LTOT were
identified during the open study period with
questionnaires completedby 89(98%) (Table IV).
Of the subjects prescribed LTOT during the
restricted period, two subjects are still alive. The
median survival time afterprescription was 19 m
(0-104). From the open period, survival data was
available on 107 of the 129 subjects prescribed
LTOT and of these 17 (16%) are still alive. The
median survival time afterprescription was 22 m
(0-94) and for subjects who fulfilled all criteria
for provision of LTOT was 18 m (0-90). The
cumulative survival curve for all subjects and for
those whofulfilledallcriteriais showninfigure 2.
TABLE III
Comparative mean spirometric and arterial blood gases (± standard deviation (SD))for subjects
prescribed home oxygen by generalpractitioners and consultantphysicians during open
prescribing.
General Practitioner Physician
Installations 14 115
Female 3 46
FEV1 (I) 0.46 (0.13) 0.97 (0.69)
PaO2 (kPa) 5.89 (0.64) 6.59 (1.75)
PaCO2 (kPa) 6.5 (0.7) 6.59 (1.69)
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TABLE IV
Advice given when home oxygen prescribed and actual usage by subjects during period ofopen
prescribing.
Open -
Open - consultant General Practitioner
n (%) Total n=75 n (%) Total n=14
Duration of use no advice 2 (3) 0 (0)
prn use 3 (4) 10 (71)
< lOh/day 1 (1) 1 (7)
10-15 h /day 14 (19) 1 (7)
> 15 h/ day 55 (73) 2 (14)
Flow rate not stated 5 (7) 14 (100)
Incorrect use despite correct advice 7 (9) not applicable
Smoking 0 (0) 3 (21)
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Fig 2. Cumulative survival curvesforpatientsprescribed
oxygen concentrators during the period of open
prescribing (closed squares - all subjects, open
squares - subjects fulfilling prescribing criteria).
DISCUSSION
LTOT for patients with COPD and respiratory
failure prolongs survival," 2improves quality of
life,4 reduces hospitalisations5 and improves
intellectual performance.6 This study documents
prescribing habits of oxygen concentrators in
Northern Ireland but did not examine oxygen
provision in other ways, notably via cylinders.
During open prescribing the number of
concentrators provided (129, 4 per 100,000
population) was lower than the UK average of
8000 (16 per 100,000 population).7 It has been
estimated that the prevalence of hypoxia in the
community sufficienttorequireLTOTis 0.3% of
thepopulationovertheageof45years8 suggesting
significant underprovision ofLTOT in Northern
Ireland. There is a need for accurate epidemio-
logical data on the prevalence of hypoxia in
Northern Ireland.
Whilst the prescribing criteria for both periods
were different, this study demonstrates that a
significantnumberofconcentrators wereinstalled
without adherence to the stated criteria, and to
patientgroupswhohavenotbeenshowntobenefit
from long term oxygen provision (figure 1). This
occurred independent of the source of the
prescription i.e. either physician-advised or by
the general practitioner. Earlier studies have
demonstratedthatfewerthan60% ofprescriptions
forlongtermoxygenwereontherecommendation
of a respiratory physician and only 43-63% of
patients fulfilled the Department of Health
criteria.9"10"11 Our figure of 32% during a
comparable period is even lower despite the high
proportion (89%) provided on the advice of
respiratory physicians.
The low prescribing rate coupled with the failure
to prescribe according to the guidelines suggests
that many who could benefit from LTOT are not
receiving it. The reasons for this are probably
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multifactorial but seem likely to include lack of
awareness of the current criteria. Our clinical
experience indicates that many who attend
primary care physicians and hospital based
services are not referred for investigation of
oxygen status. A greater awareness of this issue
coupledwithpracticesemployedtoassessoxygen
status is required. More widespread use of
oximetrybygeneralpractitioners andsubsequent
referralforformalassessmentifoxygensaturation
is low would help in the primary care setting. In
hospital, the useofacommittedrespiratory nurse
and assessment athome after discharge using ear
lobegases, whichistechnicallyeasiertoperform,
would ensure hypoxic patients are followed up.
The median survival time was not significantly
different for both periods ofprescribing. During
the open period, survival was similar for the
group as a whole, compared to subjects in whom
the prescribing criteria were fulfilled. In this
latter group, the age at prescription and the poor
survival suggests intervention at arelatively late
stage of the disease. Improvements in survival
are only likely to be achieved by intervention at
an earlier stage.
In terms of advice given, patients were more
likelytoreceiveappropriateadviceaboutduration
of daily use and flow rates when the LTOT was
prescribed in hospital, though again a significant
proportion were given inappropriate advice from
both physicians and general practitioners. Most
subjects received advice about flow rate when
LTOT was prescribed from hospital; this is
important, especially in patients with Type 2
respiratory failure. The aim of LTOT is to raise
the PaO2 above 8 kPa without excessive
hypercapnia3 and regular follow up at least twice
yearlybyarespiratoryconsultantisrecommended
by the British Thoracic Society.3 The majority of
patients followed the advice which was given
even when inaccurate. Previous studies have
demonstrated that compliance is better when
advice is received from a respiratory physician
compared to general practitioners.9 Since the
number of general practitioner prescriptions in
our study was small we cannot comment on this
but adherence to advice presupposes that the
advice is both given and appropriate.
In our study, three subjects were still smoking
afterprescriptionofLTOTinbreachofguidelines.
This figure is less than in other studies which
have demonstrated 20%, 19% and 14% still
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smoking respectively7' 9 12assessed by review of
case notes or questionnaire. This suggests our
populationiseithermorecompliantorlesshonest
than other studies. Cessation ofsmoking was not
assessed by an objective measure such as
carboxyhaemoglobin level or urinary cotinine
levels. There is obvious concern over safety as
wellas thelikelybenefitofLTOTinpatients who
continue to smoke.
This study demonstrates an inadequate rate of
prescribing andalackofconformitytoguidelines
in the provision of LTOT in Northern Ireland.
Greater awareness of the potential of LTOT to
improve quality of life in patients with chronic
lung disease is needed. We would suggest that
familiarisation with the criteria by general
practitioners, practice nurses and hospital
physicians, formal written advice at the time of
prescription, appropriate follow up and regular
patient education on the use of LTOT would
address these problems to a substantial degree. A
further audit should be performed to examine the
current provision of LTOT in Northern Ireland.
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